Navigation Links
Amarin Reports Top-Line Results of two Phase III Studies of,Miraxion in Huntington's Disease

Conference Call Begins Today at 11:00 a.m. Eastern Time

LONDON, April 24, 2007 /PRNewswire-FirstCall/ -- Amarin Corporation plc ("Amarin" or the "Company") today announces top-line results from its two Phase III clinical trials of Miraxion to treat Huntington's disease (HD). The Company conducted two Phase III double-blind, placebo-controlled studies in which HD patients were randomized to receive either placebo or 2 grams (1 gram twice daily) of Miraxion daily for six months. Study data showed no statistically significant difference in either study between Miraxion and placebo with regard to the primary and secondary endpoints.

These top-line findings are inconsistent with earlier clinical trial data that showed statistical significance in a subset of HD patients with a CAG repeat length of less than or equal to 44.

The primary endpoint of the trials was a change in the Total Motor Score 4 (TMS-4) component of the Unified Huntington's Disease Rating Scale (UHDRS). TMS-4 has been shown to be a sensitive measure of movement disorder in patients with HD. In addition, secondary endpoints included cognition and Total Functional Capacity outcomes. Miraxion was found to be safe and well-tolerated by patients.

Commenting on today's announcement, Rick Stewart, Chief Executive Officer of Amarin, said, "We are extremely surprised and disappointed by these top-line results, and we are analyzing the data in order to better understand the full and complete data set and outcomes. We are particularly disappointed that, at this time, we are not in a position to bring any positive news to those patients who are suffering from this devastating disease and to the broader HD community."

"Despite this setback with Miraxion to treat HD, we remain committed to developing Amarin's substantial central nervous system (CNS) development pipeline." commented Mr. Stewart. "We continue to evaluate the potential of
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/15/2014)... N.Y. , Dec. 15, 2014 As ... SPL (Structured Product Labeling) markup language standard, content teams ... understanding and skills to work with the standard. Starting ... series of three webinars on the benefits and the ... one-hour webinars will be facilitated by Howard Shatz ...
(Date:12/14/2014)... GREENVILLE, S.C. , Dec. 14, 2014  ChartSpan, ... become the most downloaded iPhone and iPad medical app ... Photo - http://photos.prnewswire.com/prnh/20141214/164317 ... with the ability to request, manage and send electronic ... of innovative entrepreneurs who grew tired of waiting for ...
(Date:12/13/2014)... 12, 2014 Mindray Medical International Limited ("Mindray", ... and marketer of medical devices worldwide, today announced shareholder ... held in Hong Kong on ... shareholders voted to re-elect incumbent directors Li Xiting and ... shareholders did not re-elect Peter Wan as ...
Breaking Medicine Technology:Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3ChartSpan Becomes The Most Downloaded Medical App in America 2ChartSpan Becomes The Most Downloaded Medical App in America 3Mindray Announced Shareholder Resolutions Post 2014 Annual General Meeting 2
... Sept. 22 AstraZeneca today,announced that the United ... additional six-month period of exclusivity to market CASODEX(R),(bicalutamide) ... 1, 2009. AstraZeneca has been working with the ... of CASODEX in a pediatric,setting but will not ...
... a biotech company,focused on developing novel therapeutics for ... commercial and manufacturing expertise to,the Company,s senior management ... clinical trials of ENB-0040 for the treatment of,hypophosphatasia., ... Enobia,s Vice President, Chief,Commercial Officer, and Jayant Aphale, ...
Cached Medicine Technology:AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA 2AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA 3AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA 4Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team 2Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team 3
(Date:12/17/2014)... Kathleen Doheny HealthDay ... Chronic sleep loss is rampant in America, and work commitment ... is the No. 1 sleep killer," said Dr. Mathias Basner, ... the University of Pennsylvania Perelman School of Medicine. A ... older, found that work is the main activity exchanged for ...
(Date:12/15/2014)... Cancer researchers have just published an important new report ... pleural mesothelioma. Surviving Mesothelioma has just posted an article ... to read it now. , Doctors at Harvard, ... York’s Langone Medical Center performed complete genetic analyses on ... effort to pinpoint the genes that are most likely ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), ... a new study providing evidence on the impact of ... children. , Sufficient enough evidence already exists showing a ... juice drinks, with the onset of tooth decay. One ... listed as 100% fruit juice, meaning it is completely ...
(Date:12/15/2014)... a leading mobile app development company , custom ... which allows users to keep track of wines they ... right wine. At the center of WineMatch is ... wine information. All this information is assembled to help ... are close counterparts to one another are called Matches. ...
(Date:12/15/2014)... 15, 2014 Health Dialog, a ... today that it has received Patient Oriented Accreditation ... for its Disease Management (DM) Programs for asthma, ... coronary heart disease and diabetes. This marks the ... Health Dialog’s Disease Management (DM) Programs, reaffirming Health ...
Breaking Medicine News(10 mins):Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2
... traditional Indian medicine, a four-year degree course in Ayurveda ... for the first time in eastern India//. ... its kind in the country after Gujarat, would be ... in joint venture with West Bengal Health Department under ...
... postmenopausal women has shown that those who indulged in six ... a 3 percent reduction in risk of type 2 diabetes, ... the scientists were not able to place their finger on ... yet they strongly feel that the presence of antioxidants and ...
... Now, Britain's reputed pediatricians, nearly 30 of them have called ... ,Infact they have issued a letter to the public ,that ... triple shots of MMR. ,They have appealed to the ... furore over the supposed link between MMR and autism, especially ...
... a University of Alabama biostatistician has compiled a report on ... assisted in this venture by 19 other scientists in the ... at more than 100 studies on the reasons for obesity ... could be an answer ,* Inadequate sleep: Sleep ...
... in New Zealand. Hence Pharmac decided to fund for the new ... level. // ,It has decided to give Insulin Glargine ... , Murray Dear who is the president for the Diabetes New ... the incidence of diabetes. ,He also said that the ...
... could increase their chances of breast cancer, a study says. ... Agency for Research on Cancer in France analysed 1,600 women. ... susceptibility genes) mutations who had undergone a chest X-ray were ... who had never undergone the procedure. ,Women who ...
Cached Medicine News:
Compression Bra...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
... Test is a clinical chemistry assay that ... the cobalt binding capacity of albumin in ... the early 1990s, IMA is produced when ... tissue in the heart. During ischemia, the ...
Medicine Products: